QL2: ESTIMATING PATIENTS' PREFERENCES IN TREATMENT CHOICES INVOLVING RISK: A NEW MODIFIED STANDARD GAMBLE METHOD  by Walshe, R
414 Abstracts
the Beck at six months (48% vs. 37%, P  .05). Greater
quantitative reduction in symptom scores on the Hamil-
ton at six months (10.4 vs. 8.1, P  .006) were observed.
Telehealth care improved mental functioning at six weeks
(47.1 vs. 42.6, P  .004) and treatment satisfaction at six
weeks (4.41 vs. 4.17, P  .004) and six months (4.20 vs.
3.94, P  .001). Medication adherence was the same in
all groups and adding peer support to telehealth care did
not improve the main outcomes.
CONCLUSION: Nurse Telehealth Care improves clinical
outcomes of antidepressant treatment, improves patient
satisfaction, and fits well in primary care. The nurse tele-
health care program has been implemented in Maine,
Ohio and Southern California.
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OBJECTIVE: Newer antipsychotics have been associated
with increased weight gain. There is also mounting evi-
dence that this leads to noncompliance and a lower qual-
ity of life. Gaining weight is also undesirable for health
reasons and may lead to increased use of health-care re-
sources. This study considers the association between
weight gain and acute service use for patients with
schizophrenia.
METHODS: Questionnaires were mailed to people with
schizophrenia identified through National Alliance for
the Mentally Ill and the National Mental Health Associa-
tion in spring 2000 (n  390). Data presented here are
from the 345 respondents who reported weight loss (n 
94, 27%), no weight change (n  106, 31%), some
weight gain (1–14lbs; n  70, 20%), and significant
weight gain (15lbs; n  75, 22%) within the last six
months. Acute service use was defined as emergency
room (ER) visit or hospitalization. Cost values were
those reported in Ernst and Hay (1994). For each individ-
ual, total costs were computed by summing across cate-
gories.
RESULTS: The group reporting significant weight gain
was significantly more likely to use acute services than
the other three groups (p  .001 for hospitalization, p 
.005 for ER visit). The association remained significant
when controlling for other variables in multivariate anal-
yses, including age, gender, ethnicity, and overall distress.
Overall costs were highest for those who gained 15 or
more pounds ($9,486). Those who lost weight incurred
costs of $7,400, those who did not change weight in-
curred costs of $4,095, and those who gained 1–14
pounds incurred costs of $3,647.
DISCUSSION: Our preliminary results suggest that re-
cent weight gain is associated with greater use of acute
services and higher costs. There are several plausible ex-
planations. For example, physicians might change medi-
cations for people doing poorly (e.g., start a new medica-
tion after an acute psychiatric episode). Another possibility
is that acute medical services are more likely to be needed
after an episode of rapid weight gain.
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OBJECTIVE: To predict Health State Values (HSV) from
health-related quality of life (HRQL) assessments could,
if possible, be a fruitful way to use HRQL values for
health-economic evaluations. With this in mind, we in-
vestigated to what degree values from the EuroQol in-
strument, the EQ-5D index, and the EQ-VAS visual ana-
log scale, could be predicted using HRQL measures for
patients with respiratory diseases.
METHODS: Data from two surveys of patients with res-
piratory disease were used for this evaluation. The first
data set was from 206 patients in Hungary suffering from
asthma, and the other was from 120 patients in the
northern part of Sweden with COPD. Both surveys in-
cluded patients with different severities of the diseases.
The HRQL instruments used in both surveys were the SF-
36, a generic instrument, and St George’s Respiratory
Questionnaire (SGRQ), a disease-specific instrument. The
two data sets were analyzed separately using a multiple
logistic regression model in a stepwise manner to predict
EQ-5D and EQ-VAS from the eight domains of SF-36 and
the three domains of SGRQ, after transformation of EQ-
5D and EQ-VAS to a 0–1 range.
RESULTS: The amount of variation in both the EQ-5D
and EQ-VAS that could be explained from the combined
HRQL measures was at most 56%. EQ-5D had larger
values than EQ-VAS. Using SF-36 domains only as pre-
dictors gave marginally lower values. The two domains
from SF-36 with best predictability explained about 90%
of the reduction achieved with all 11 domains together
from the two HRQL-measures, indicating correlation be-
tween the different domains.
CONCLUSION: Values for EQ-5D and EQ-VAS pre-
dicted from SF-36 and SGRQ have moderate precision
and should be used cautiously.
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OBJECTIVE: Cost-effectiveness, -utility and -benefit
analyses have made a substantial impact on heath care.
Current approaches are methodologically coherent and
provide a basis for improved resource allocation. As has
been noted before, they are based on expected (average)
outcome and do not take into account patients’ risk pref-
erences, which are important aspects of clinical decision-
making. From a patient’s perspective, a treatment associ-
ated with a lower level of expected clinical benefit may be
preferred if it has better worst-case scenario than a treat-
ment with higher expected (average) benefit. We analyze
decision-scientific methodology in order to incorporate
risk preferences into the framework of outcome and util-
ity studies.
METHODS: Concepts of risk preferences in decision-
making from economics and management science are de-
scribed, and their applicability to a clinical context is
tested using a decision tree model. Methods analyzed in-
clude the Bayes-Principle of expected value (m-principle),
the m-s-principle, risk restriction with given outcome and
the Bernoulli-Principle. The absence of risk preferences in
the QALY (quality adjusted life years) and HYE (healthy
years equivalent) concepts is shown mathematically.
RESULTS: Current methodological concepts used in out-
comes research do not adequately incorporate patients’
risk preferences. On the basis of a modified standard
gamble approach a method of obtaining risk preferences
for given treatment outcome is developed. It leads to the
determination of relative marginal utilities and may be
used in choosing health-care interventions by considering
relative marginal costs.
CONCLUSION: Patients’ risk preferences should be taken
into account in outcome and utility analyses involving sub-
stantial risks. The approach proposed here may improve
the empirical estimation of patients’ preferences and the
quality of resource allocation in health care.
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OBJECTIVE: Support for the reliability and validity of
the Medical Outcomes Study (MOS) Sleep Scale was pro-
vided in the MOS sample of 3445 individuals with
chronic illness. We sought to extend this work by evalu-
ating the psychometric properties of the MOS-Sleep Scale
in the US general population.
METHODS: The MOS-Sleep Scale is a 12-item, self-re-
ported survey that yields six subscales: sleep disturbance,
snoring, awaken short of breath or with headache, quan-
tity of sleep, sleep adequacy, and somnolence as well as a
nine-item sleep problem index. The subscales and prob-
lem index are scored on a 0 to 100 range, with higher
scores indicating more of the domain being measured.
We administered the MOS measure by telephone to a na-
tionally representative sample of 1011 US adults aged 18
and older in January 2001.
RESULTS: The average age of the sample was 46; 51%
were female and 74% were white. Internal consistency
reliability estimates for the MOS-Sleep scales tended to
be adequate: sleep disturbance (4 items, alpha  0.80);
sleep adequacy (2 items, alpha  0.82); sleep somnolence
(3 items, alpha  0.63); and nine-item sleep problems in-
dex II (alpha  0.83). Adjusting for age and gender,
MOS patients reported significantly more quantity of
sleep (t  3.27, P  .002), but significantly worse sleep
disturbance (t  5.08, P  .001), snoring (t  2.16, P 
.05), shortness of breath (t  4.59, P  .001), sleep ade-
quacy (t  2.39, P  .05), somnolence (t  5.10, P 
.001), and sleep problems (t  3.27, P  .002) than the
general US population.
CONCLUSIONS: The MOS-Sleep Scale was found to
have good internal consistency reliability and to discrimi-
nate between patients with chronic illness and the US
general population. Further work is needed to compare
the MOS-Sleep Scale results with objective measures of
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OBJECTIVE: To analyze health-related quality of life
among people with sleeping problems from an epidemio-
logical perspective.
METHOD: A cross-sectional survey on a sample aged
between 20 and 84 years in the county of Uppland, Swe-
den yielded a response in 5404 patients (68%). A recall
period of two weeks was used for sleeping problems and
use of sleeping medication. The SF-36, used to measure
HRQoL, covers eight domains of health: physical func-
tion (PF); role limitation because of physical health (RP);
bodily pain (BP); general health perception (GH); vitality
(VT); social functioning (SF); role limitation because of
emotional health problem (RE), and mental health (MH).
Linear regression analysis was employed for the multi-
variate analyses.
RESULTS: In all, 20.3% of the population reported
sleeping problems. Sixteen percent had experienced sleep-
ing problems but had not used sleeping medication while
4.3% had used medication. The prevalence of sleeping
problems was of the same magnitude between the ages of
20 to 74 years (around 20%) but higher among those
aged 75 to 84 years (29.5%). Sleeping problems were
more prevalent among women (23.8%) than men (16.1%).
The use of sleeping medication increased by age. Among
